San Mateo, CA, United States of America

Suleyman Bahceci

USPTO Granted Patents = 3 

Average Co-Inventor Count = 18.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2012-2014

Loading Chart...
3 patents (USPTO):Explore Patents

Title: **Suleyman Bahceci: Innovator in Cancer Treatment**

Introduction

Suleyman Bahceci, an accomplished inventor based in San Mateo, CA, has made significant contributions to the field of cancer research through his innovative work. With a total of three patents, Bahceci is recognized for his expertise in developing compounds that have the potential to revolutionize cancer treatment.

Latest Patents

Among his most notable inventions are his patents on "Inhibitors of the Hedgehog Pathway." These patents focus on compounds described by specific formulas, with the potential to be used as pharmaceutically acceptable salts, hydrates, or solvates. Bahceci's innovative compounds show promise for treating cancer, offering new avenues for therapeutic intervention.

Career Highlights

Suleyman Bahceci is affiliated with Exelixis Patent Company LLC, a company known for its dedication to pioneering cancer therapies. His career is marked by a commitment to advancing understanding and treatment methodologies in oncology through his inventive insights.

Collaborations

Bahceci collaborates with esteemed colleagues such as William Bajjalieh and Jeff Z Chen, leveraging their combined expertise to further the research and development of groundbreaking cancer treatments. This collaboration highlights the importance of teamwork in the innovative process.

Conclusion

Suleyman Bahceci stands out as a key figure in the domain of cancer research and innovation. His dedication to creating effective treatment options exemplifies the impactful role of inventors in advancing medical science. With continued efforts, he is poised to contribute even more to the fight against cancer through his innovative inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…